What is the recommended timeframe after stopping Naltrexone (naltrexone) before starting Suboxone (buprenorphine/naloxone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Waiting Period After Stopping Naltrexone Before Starting Suboxone

For oral naltrexone, wait 2-3 days after the last dose before initiating Suboxone (buprenorphine/naloxone). For extended-release naltrexone injections, wait 24-30 days before starting buprenorphine therapy.

Oral Naltrexone Washout Period

The standard waiting period is 2-3 days after discontinuing oral naltrexone before starting buprenorphine. This timeframe is based on the pharmacokinetics of naltrexone and its active metabolite 1.

Pharmacologic Rationale

  • Naltrexone has a plasma half-life of only 4 hours, but its active metabolite (6-β-naltrexol) has a half-life of 13 hours 1, 2
  • The metabolite accumulates during long-term therapy, and antagonist effects persist for 2-3 days after stopping 1
  • This 2-3 day washout period allows sufficient clearance of opioid receptor blockade to permit buprenorphine binding 2

Clinical Application

The 2-3 day waiting period is supported by consensus guidelines from the Society for Perioperative Assessment and Quality Improvement (SPAQI), which recommend holding oral naltrexone for 2-3 days before procedures requiring opioid administration 1. This same principle applies when transitioning to buprenorphine, as buprenorphine is a partial mu-opioid agonist that requires available receptor sites to bind effectively.

Extended-Release Naltrexone Washout Period

For extended-release naltrexone injections (Vivitrol), a much longer waiting period of 24-30 days after the last injection is required before starting Suboxone 1, 2.

Why the Extended Wait?

  • Extended-release formulations provide sustained naltrexone levels for approximately one month 1
  • Receptor upregulation may occur with long-term extended-release naltrexone therapy, potentially requiring even longer washout periods 1
  • Starting buprenorphine too early after extended-release naltrexone can result in inadequate therapeutic effect due to persistent receptor blockade 2

Critical Clinical Considerations

Precipitated Withdrawal Risk

Starting buprenorphine while naltrexone is still blocking opioid receptors will not precipitate withdrawal in the traditional sense (since naltrexone is already an antagonist), but it will prevent buprenorphine from providing its therapeutic effects, potentially leaving the patient vulnerable to relapse 2.

Monitoring During Transition

  • Patients transitioning from naltrexone to buprenorphine require close monitoring during the washout period 3
  • The patient must be opioid-free during this transition to avoid precipitated withdrawal when buprenorphine is eventually initiated 4
  • Withdrawal symptoms during the naltrexone washout period may require symptomatic management with clonidine, antiemetics, or other supportive medications 5

Reverse Transition Considerations

Research demonstrates that when transitioning in the opposite direction (from buprenorphine to naltrexone), withdrawal patterns differ significantly, with peak withdrawal occurring around day 5 when naltrexone is started during buprenorphine taper 3, 5. However, when properly managed with overlapping therapy, naltrexone can be started as early as day 2 of buprenorphine taper with acceptable withdrawal symptoms 5.

Common Pitfalls to Avoid

  • Do not start buprenorphine too early after extended-release naltrexone—the 24-30 day waiting period is essential and cannot be shortened 1, 2
  • Do not assume oral naltrexone clears quickly just because its half-life is short—the active metabolite accumulation requires the full 2-3 day washout 1, 2
  • Do not fail to provide supportive care during the transition period, as patients may experience cravings or mild withdrawal symptoms while waiting to start buprenorphine 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Naltrexone Effects During Buprenorphine Taper

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.